Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brepocitinib in Systemic Lupus Erythematosus
NCT03845517Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial of brepocitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Pfizer. Primary endpoint: SLE Responder Index-4 at 52 weeks. Started Apr 2019; status: completed.
02
Drugs
brepocitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03845517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845517.